Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Athenex Inc (ATNX)

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 361,809
  • Shares Outstanding, K 109,308
  • Annual Sales, $ 144,390 K
  • Annual Income, $ -146,180 K
  • 60-Month Beta 0.61
  • Price/Sales 2.53
  • Price/Cash Flow N/A
  • Price/Book 2.32
Trade ATNX with:

Options Overview Details

View History
  • Implied Volatility 124.37%
  • Historical Volatility 55.71%
  • IV Percentile 77%
  • IV Rank 37.66%
  • IV High 246.55% on 02/18/21
  • IV Low 50.57% on 10/06/20
  • Put/Call Vol Ratio 0.02
  • Today's Volume 116
  • Volume Avg (30-Day) 144
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 4,939
  • Open Int (30-Day) 5,852

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.32
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.50
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +4.75%
on 09/13/21
3.91 -15.35%
on 09/02/21
+0.02 (+0.61%)
since 08/20/21
3-Month
3.12 +6.09%
on 08/20/21
5.13 -35.48%
on 06/28/21
-1.41 (-29.87%)
since 06/22/21
52-Week
3.12 +6.09%
on 08/20/21
15.00 -77.93%
on 02/10/21
-9.53 (-74.22%)
since 09/22/20

Most Recent Stories

More News
Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced...

ATNX : 3.31 (-0.90%)
Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 3.31 (-0.90%)
Athenex (ATNX) Reports Q2 Loss, Misses Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and -0.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ATNX : 3.31 (-0.90%)
Athenex: Q2 Earnings Snapshot

BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Thursday reported a loss of $34.3 million in its second quarter.

ATNX : 3.31 (-0.90%)
Athenex Provides Second Quarter 2021 Corporate and Financial Update

Updated investors on FDA Type A Meeting for oral paclitaxel

ATNX : 3.31 (-0.90%)
Athenex Announces Additional Licensing Agreements for Tirbanibulin

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced...

CSLLY : 113.2900 (+0.72%)
ATNX : 3.31 (-0.90%)
Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 3.31 (-0.90%)
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

CDXS : 25.49 (+1.07%)
ATNX : 3.31 (-0.90%)
BCYC : 43.29 (+2.22%)
ARQT : 23.54 (+4.11%)
Athenex Announces European Commission Approval of Klisyri(R) (tirbanibulin) for the Topical Treatment of Actinic Keratosis

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced...

ATNX : 3.31 (-0.90%)
Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 3.31 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

3rd Resistance Point 3.52
2nd Resistance Point 3.46
1st Resistance Point 3.38
Last Price 3.31
1st Support Level 3.24
2nd Support Level 3.18
3rd Support Level 3.10

See More

52-Week High 15.00
Fibonacci 61.8% 10.46
Fibonacci 50% 9.06
Fibonacci 38.2% 7.66
Last Price 3.31
52-Week Low 3.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar